Iterum Therapeutics to Present Data at ASM Microbe 2024
Iterum Therapeutics (Nasdaq: ITRM) has announced its participation in the ASM Microbe 2024 conference in Atlanta, Georgia, from June 13-17, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iterum Therapeutics (Nasdaq: ITRM) has announced its participation in the ASM Microbe 2024 conference in Atlanta, Georgia, from June 13-17, 2024. The company will present a poster titled 'In Vitro Assessment of Sulopenem against Mycobacterium avium Complex' on June 16, 2024, from 10:00 a.m. to 4:00 p.m. in the Exhibit Hall. The presentation falls under the category of 'New Antimicrobial Agents' and will be delivered by Dr. Steven I. Aronin. The poster will be available on Iterum Therapeutics' website after the conference.
Positive
- Iterum Therapeutics will present promising in vitro data on Sulopenem.
- The company is participating in a prestigious event, ASM Microbe 2024.
- Positive exposure for Iterum Therapeutics and its advancements in antibiotics.
Negative
- No financial data or immediate commercial impact presented in the announcement.
- Lack of concrete clinical trial results or FDA approvals.
- Potentially impact on stock price due to the absence of immediate business developments.
Details
News Market Reaction – ITRM
The recorded move for ITRM in the trading session of this news was -0.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will present a poster at the American Society for Microbiology (ASM) Microbe 2024 meeting, being held June 13-17, 2024, in Atlanta, Georgia.
Data to be presented includes:
Presentation title: In Vitro Assessment of Sulopenem against Mycobacterium avium Complex
Presentation type/category: AAR08 New Antimicrobial Agents (In Vitro and In Vivo Studies) (AAR-Sunday-517)
Presenter: Steven I. Aronin, MD
Time/location: June 16, 2024, 10:00 a.m. – 4:00 p.m.; Exhibit Hall
This poster will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.